NNRTIs in Development
- MK-1439 -- A Novel NNRTI For HIV Treatment (Video) (March 15, 2013)
From HIVandHepatitis.com
- Merck's Non-Nuke MK-1439 Shows Antiviral Activity, Is Safe and Well Tolerated (March 11, 2013)
From AIDSmeds.com
- Novel Drug Shows "Strong" Anti-HIV Effect (March 6, 2013)
From MedPage Today
- New NNRTI MK-1439 Shows Promise in Early Clinical Trial (March 6, 2013)
From aidsmap.com
- Seven-Day Monotherapy With New NNRTI Yields Sharp Viral Load Drop (March 5, 2013)
From National AIDS Treatment Advocacy Project
- An Overview of Lersivirine (October 11, 2012)
From AIDSinfo
- Merck Acquires CMX157 and EFdA and Starts Phase 2 Study for New NNRTI (September/October 2012)
To read PDF, click here.
In HIV Treatment Bulletin, from HIV i-Base
On TheBodyPRO.com
- Studies on Pipeline Antiretrovirals Reveal New Data on Possible Drug Interactions (May/June 2012)
To read PDF, click here.
In HIV Treatment Bulletin, from HIV i-Base
On TheBodyPRO.com
- Lersivirine: 48-Week Results Compared to Efavirenz in Phase 2 Treatment-Naive Study (July/August 2011)
To read PDF, click here.
In HIV Treatment Bulletin, from HIV i-Base
- New Drug Adds to Arsenal Against AIDS (July 25, 2011)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
VIEW ALL ARTICLES
|
Advertisement
|